CD38 and neoplasm: Isatuximab is a distinct anti-CD38 monoclonal antibody that binds a unique epitope and is reported to induce tumor cell death through multiple mechanisms, including direct apoptosis, antibody-dependent cellular cytotoxicity, phagocytosis, and inhibition of CD38 enzymatic activity [11,12].